Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51)

Diabetologia
P M ClarkeUKPDS Group. United Kingdom Prospective Diabetes Study

Abstract

To estimate the economic efficiency of intensive blood-glucose control with metformin compared with conventional therapy primarily with diet in overweight patients with Type II (non-insulin-dependent) diabetes mellitus. Cost-effectiveness analysis based on patient level data from a randomised clinical controlled trial involving 753 overweight (> 120% ideal body weight) patients with newly diagnosed Type II diabetes conducted in 15 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study. Subjects were allocated at random to an intensive blood-glucose control policy with metformin (n = 342) or a conventional policy primarily with diet (n = 411). The analysis was based on the cost of health care resources associated with metformin and conventional therapy and the estimated effectiveness in terms of life expectancy gained from within-trial effects. Intensive blood-glucose control with metformin produced a net saving of 258 Pounds per patient (1997 United Kingdom prices) over the trial period (median duration of 10.7 years) due to lower complication costs, and increased life expectancy by 0.4 years (costs and benefits discounted at 6%). As metformin is both cost-saving in the Uni...Continue Reading

Citations

Jun 20, 2002·Pharmazie in unserer Zeit·Holger Neye
Apr 19, 2005·Diabetologia·P M ClarkeUNKNOWN UKPDS 72 United Kingdom Prospective Diabetes Study
Jul 24, 2002·Biochemical and Biophysical Research Communications·Jan JohanssonHans Jörnvall
Sep 3, 2002·Journal of the American College of Cardiology·Harlan M KrumholzA David Paltiel
Jul 27, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·A GrayUNKNOWN UKPDS Group
Jun 1, 2011·Epidemiologic Reviews·Justin B Echouffo-TcheuguiK M Venkat Narayan
Jan 22, 2010·International Journal of Clinical Practice·M Al-MaatouqK G M M Alberti
Oct 19, 2002·BMJ : British Medical Journal·Alastair GrayUNKNOWN United Kingdom Prospective Diabetes Study (UKPDS) Group
May 20, 2003·PharmacoEconomics·Maria Raikou, Alistair McGuire
Jul 28, 2012·Indian Journal of Endocrinology and Metabolism·Sanjay KalraRakesh Sahay
Nov 22, 2008·Acta Diabetologica·Dan HauptJ Lars G Nilsson
Jun 1, 2006·Expert Review of Pharmacoeconomics & Outcomes Research·Thomas SongerUNKNOWN the TODAY Study Group
Oct 18, 2011·Diabetes Research and Clinical Practice·P Andújar-PlataB Laferrère
Mar 13, 2009·Diabetes Research and Clinical Practice·Paul Zimmet
Apr 28, 2009·European Journal of Internal Medicine·Jacob DreiherAvi Porath
Dec 7, 2007·Best Practice & Research. Clinical Endocrinology & Metabolism·Julia M Bottomley, Frank D Raymond
Nov 14, 2006·Diabetes Research and Clinical Practice·Angelika Schäfer, Petra Högger
Sep 9, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·A M Gray, P Clarke
Sep 9, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·S Genuth
Aug 21, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·A M Gray
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Alexandra WardMaribel Salas
Aug 21, 2013·Upsala Journal of Medical Sciences·Sevek EngströmKurt Svärdsudd
Apr 17, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Xuanqian Xie, Hindrik Vondeling
Nov 13, 2014·Diabetes Technology & Therapeutics·Yuxin HuangWen Tan
May 26, 2012·Australian Health Review : a Publication of the Australian Hospital Association·Tshepo M RasekabaAnastasia F Hutchinson
Jul 30, 2015·The Cochrane Database of Systematic Reviews·Bianca HemmingsenJørn Wetterslev
Apr 30, 2004·Journal of Human Hypertension·A J PalmerR W Bilous
Jun 6, 2020·The Cochrane Database of Systematic Reviews·Filip GnesinBianca Hemmingsen
May 18, 2019·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Beatriz Rodríguez-SánchezRob J M Alessie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.